In HCC, cells with genetically altered high expression of Gal-1 were more resistant to sorafenib as compared with isogenic low expressing Gal-1 cells, shown by knock-in as well as knock-out systems [91]. This evidence concerns the gene GAL and hepatocellular carcinoma.